beta
Trial Radar IA
Lo studio clinico NCT07498478 per Cancro al seno è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment Fase II 94 Terapia combinata

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT07498478 è uno studio interventistico di Fase II volto a esaminare il trattamento per Cancro al seno, attualmente in arruolamento. Avviato il 17 marzo 2026, prevede di arruolare 94 partecipanti. Sotto la guida di TransThera Sciences (Nanjing), Inc., dovrebbe concludersi entro il 31 dicembre 2027. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 27 marzo 2026.
Sommario breve

The goal of this clinical trial is to learn if tinengotinib combined with fulvestrant works to treat patients with HR-Positive and HER-2-Negative or low-expressing advanced breast cancer. It will also learn about the safety of combination therapy. The main questions it aims to answer are:

  1. Does tinengotinib combined with fulvestrant reduce the tumor burden in participants?
  2. What medical problems do participants ...
Mostra di più
Titolo ufficiale

A Phase II, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TT-00420 (Tinengotinib) Tablets Combined With Fulvestrant Injection in Patients With Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2 (HER-2) Negative or Low-Expressing Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Patologie
Cancro al seno
Altri ID dello studio
  • TT00420CN15
Numero NCT
NCT07498478
Data di inizio (effettiva)
2026-03-17
Ultimo aggiornamento pubblicato
2026-03-27
Data di completamento (stimata)
2027-12-31
Arruolamento (previsto)
94
Tipo di studio
Interventistico
FASE
Fase II
Stato
In arruolamento
Scopo principale
Trattamento
Allocazione
Randomizzato
Modello di intervento
In parallelo
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
SperimentalePart B (combination therapy)
Tinengotinib at the optimal dose combined with Fulvestrant
Participants will receive tinengotinib at the optimal dose once daily with fulvestrant in 28-day cycles per protocol defined schedule.
SperimentalePart B (monotherapy therapy)
Tinengotinib
Participants will receive tinengotinib once daily in 28-day cycles per protocol defined schedule.
SperimentalePart A (dose optimization)
tinengotinib combined with fulvestrant
Participants will take tinengotinib at the starting dose of 10 mg once daily with fulvestrant to determine the optimal dose of tinengotinib in combination with fulvestrant. If not tolerated, the dose of tinengotinib will be reduced to 8 mg or 6 mg once daily.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Part A: safety evaluation parameters
Including incidence, duration, and severity of DLTs and treatment-related adverse events (TRAEs)
From signing of the informed consent until 28 days after the last dose or the end of the study (whichever occurs first), an average of 1 year.
Part B: Objective Response Rate (ORR) (RECIST v1.1)
The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1.
From first study drug administration to the end of treatment, an average of 1 year.
Assistente alla partecipazione
Criteri di eleggibilità

Età idonea
Adulto, Adulto anziano
Età minima
18 Years
Sessi idonei
Femmina
  1. Histologically or cytologically confirmed breast cancer with evidence of local recurrence or distant metastasis and no indication for surgery or radiotherapy;
  2. Breast cancer confirmed as HR+/HER2- negative or low expression by local laboratory testing based on the most recent tumor tissue sample (from either the primary or metastatic site, excluding bone lesions). HR-positive, HER2-negative or low expression as defined in this study refer to the Chinese Society of Clinical Oncology \[CSCO\] 2024 criteria;
  3. Participants must meet at least one of the following criteria: a) prior bilateral oophorectomy, or age ≥60 years; b) age <60 years, with natural amenorrhea (in the absence of medication or pathological conditions) for ≥12 months, and estradiol and FSH levels within the postmenopausal range; c) age <60 years, currently undergoing ovarian suppression therapy (e.g., LHRH agonist) and requiring continued treatment during the study, with estradiol and FSH levels maintained within the postmenopausal range;
  4. Participants who have previously failed 1-2 lines of endocrine therapy (including AI, SERD, and SERM) for recurrent or metastatic disease are eligible. Subjects with initial diagnosis showing weak ER positivity by IHC (tumor cells with nuclear staining accounting for 1%-10%) are not eligible for enrollment;
  5. Participants must have experienced disease progression after prior treatment with at least one CDK4/6 inhibitor (CDK4/6i), including in the neoadjuvant, adjuvant, or systemic treatment settings;
  6. Participants who have previously failed 0-2 lines of systemic chemotherapy (cytotoxic drugs) for recurrent or metastatic disease. Antibody-drug conjugates (ADCs) are not counted as systemic chemotherapy;
  7. ECOG ≤ 1;
  8. Participants must meet at least one of the following criteria (per RECIST v1.1): a) At least one measurable lesion as defined by RECIST v1.1 at baseline; if the only target lesion is a non-nodal lesion, its longest diameter must be ≥15 mm; b) When bone lesions are the only measurable lesions, lytic or mixed bone lesions may be selected as target lesions; subjects with only blastic bone lesions are not eligible for enrollment.
  9. Adequate organ and bone marrow function;
  10. Premenopausal participants receiving ovarian suppression therapy must agree to use adequate contraception to avoid pregnancy during the study and for at least 3 months after the end of treatment;
  11. Able to sign informed consent and comply with the protocol.

  1. Participants who are pregnant or breastfeeding;
  2. Conditions judged by the investigator as making the participant unsuitable for study drug treatment, including but not limited to: a history of severe allergy to the components or excipients of the study drug, prior treatment history with the study drug, or presence of complications that may be life-threatening in the short term (such as pleural, pericardial, or abdominopelvic effusions that cannot be controlled by drainage or other methods);
  3. Uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg), allowing for the lowest value from up to two repeat measurements;
  4. Participants with brain or central nervous system (CNS) metastases that have progressed as confirmed by imaging or clinically within 28 days before the start of treatment (e.g., evidence of new or enlarging brain metastases on imaging, new neurological symptoms attributable to brain/CNS metastases);
  5. Participants with concurrent other malignancies or hematologic malignancies that are progressing or require active treatment (excluding basal cell carcinoma of the skin, other non-invasive or indolent malignancies, or cured tumors); Hormone replacement therapy is permitted (e.g., thyroxine replacement therapy post-thyroidectomy);
  6. Participants who have received systemic treatment with corticosteroids (>10 mg/day of prednisone or equivalent dose of other corticosteroids) or other immunosuppressive medications within 14 days prior to the initiation of the study drug;
  7. Participants who have received other systemic anti-tumor therapies or treatment with investigational drugs prior to the initiation of the study drug, with a washout period of approximately 5 half-lives or 14 days, whichever is shorter;
  8. Participants who have received extensive radiotherapy or major surgery within 4 weeks prior to the initiation of the study drug, or local palliative radiotherapy within 2 weeks. (If the investigator judges that this does not pose an additional safety risk, initiation of the study drug during the washout period may be permitted with sponsor agreement.)
  9. Participants who have not yet recovered from adverse events resulting from prior anti-tumor therapy (excluding adverse events ≤ Grade 1 per CTCAE, or ≤ Grade 2 adverse events that the investigator judges do not pose a safety risk).
  10. History of severe cardiac or cerebrovascular disease;
  11. Participants who have severe gastrointestinal disease or gastrointestinal dysfunction that may lead to absorption, metabolism or excretion of the study drug, enrollment eligibility will be based on the investigator's judgment (including but not limited to total gastrotomy, short bowel syndrome).
  12. Participants who have bleeding disorders or thrombotic disorders or therapeutic anticoagulant therapy requiring INR monitoring.
  13. Participants who have received a strong CYP3A inhibitor and inducer before starting the study drug, within an interval of ≤ 2 weeks or 5 half-lives (whichever is shorter);
  14. Tested positive for the human immunodeficiency virus (HIV);
  15. Participants with active HBV infection and/or HCV infection;
  16. Participants who are unable to swallow or tolerate oral medication.
  17. The investigator determines that there are other reasons making the participant unsuitable for participation in the study.
TransThera Sciences (Nanjing), Inc. logoTransThera Sciences (Nanjing), Inc.
Contatti principali dello studio
Contatto: Caixia Sun, 025-58216298, [email protected]
13 Centri dello studio in 1 paesi

Guangdong

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Kun Wang, MD, Contatto
Non ancora in arruolamento

Hubei

Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Haijun Yu, MD, Contatto
Non ancora in arruolamento

Hunan

Hunan Cancer Hospital, Changsha, Hunan, China
Quchang Ouyang, MD, Contatto
Non ancora in arruolamento

Jiangsu

Jiangsu Province Hospital, Nanjing, Jiangsu, China
Yongmei Yin, MD, Contatto
Non ancora in arruolamento

Shandong

Shandong Cancer Hospital, Jinan, Shandong, China
Huihui Li, MD, Contatto
Non ancora in arruolamento
Linyi Cancer Hospital, Linyi, Shandong, China
Guozhu Liu, MD, Contatto
In arruolamento

Zhejiang

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Hai Hu, MD, Contatto
Non ancora in arruolamento
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China
Binghe Xu, MD, Contatto
In arruolamento
Beijing Cancer Hospital, Beijing, China
Huiping Li, MD, Contatto
Non ancora in arruolamento
The First Medical Center, Chinese PLA General Hospital, Beijing, China
Weihong Zhao, MD, Contatto
Non ancora in arruolamento
Southwest Hospital, Chongqing, China
Yi Zhang, MD, Contatto
Non ancora in arruolamento
Fudan University Shanghai Cancer Center, Shanghai, China
Hongxia Wang, MD, Contatto
Non ancora in arruolamento
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Zhongsheng Tong, MD, Contatto
Non ancora in arruolamento